Logo
x

Search

Subscribe Now

 EMA

New Drug Designations - June 2024

New Drug Designations - June 2024

  • July 30, 2024
Bio-Thera Reports the EMA’s Approval of Avzivi (Biosimilar, Avastin) for Treating Multiple Indications

Bio-Thera Reports the EMA’s Approval of Avzivi (Biosimilar, Avastin) for Treating Multiple Indications

  • July 30, 2024
Dr. Reddy’s Ituxredi (Biosimilar, MabThera) Receives the CHMP’s Positive Opinion

Dr. Reddy’s Ituxredi (Biosimilar, MabThera) Receives the CHMP’s Positive Opinion

  • July 29, 2024
Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU

Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU

  • July 24, 2024
Certa Therapeutics’ FT011 Gains the EMA’s Orphan Drug Designation to Treat Systemic Sclerosis

Certa Therapeutics’ FT011 Gains the EMA’s Orphan Drug Designation to Treat Systemic Sclerosis

  • July 22, 2024
BMS Reports the EMA’s Validation of Application for Opdivo Plus Yervoy to Treat Hepatocellular Carcinoma

BMS Reports the EMA’s Validation of Application for Opdivo Plus Yervoy to Treat Hepatocellular Carcinoma

  • July 19, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.